GLP-1 Drugs and Ankle Osteoarthritis Care

A retrospective study published in Foot & Ankle Specialist in August 2026 found that adults with obesity who took a GLP-1 receptor agonist needed fewer ankle joint injections and fewer total ankle replacements than similar patients who did not take one^[1]. The same dataset found a different pattern in a second group: adults with type 2 diabetes who took a GLP-1 drug needed more ankle arthroscopy, not less. The drug class covered in the analysis includes semaglutide, liraglutide, dulaglutide, exenatide and lixisenatide.

What the researchers actually measured

The research team, based at Johns Hopkins, used the TriNetX Analytics Network, a database that pools de-identified electronic health records from dozens of health systems^[1]. They identified adults diagnosed with obesity (a body mass index of 30 or higher) or type 2 diabetes between 2016 and 2020, then split each group into GLP-1 users and non-users. A GLP-1 user was defined as someone with at least two prescriptions for semaglutide, liraglutide, dulaglutide, exenatide or lixisenatide, separated by at least six months^[1]. After matching patients on age, sex and other health conditions, the obesity comparison included 3,089 patients per group and the diabetes comparison included 8,117 patients per group.

Three treatment outcomes were tracked over time: an ankle joint injection, ankle arthroscopy or debridement (a scope procedure to clean out damaged tissue), and total ankle arthroplasty or arthrodesis (joint replacement or fusion, the two surgical options for advanced ankle arthritis).

The numbers moved in different directions depending on the group

In the obesity cohort, GLP-1 users had a lower risk of needing an ankle injection (hazard ratio 0.8, 95% confidence interval 0.6 to 0.9) and a lower risk of needing total ankle arthroplasty or arthrodesis (hazard ratio 0.5, 95% confidence interval 0.3 to 0.9) than non-users^[1]. GLP-1 users in this cohort also lost more body weight over five years of follow-up.

In the diabetes cohort, the pattern reversed for one outcome: GLP-1 users had a higher risk of needing ankle arthroscopy (hazard ratio 1.9, 95% confidence interval 1.2 to 3.2) than non-users^[1]. The authors did not report a matching benefit on injections or joint replacement in that group.

Weight loss, not a claim about cartilage, and a database, not a trial

The authors frame their obesity-cohort finding around weight-loss-mediated joint load reduction: less body weight means less mechanical stress moving through the ankle joint. That is a different mechanism from a drug acting directly on inflamed cartilage or bone, and the study does not test or claim a direct anti-inflammatory effect on the ankle joint itself.

It is also a retrospective cohort study built from insurance and health-record data, not a randomized trial. That design can show an association between GLP-1 use and treatment patterns, but it cannot rule out that GLP-1 users differed from non-users in ways the statistical matching did not fully capture, such as how consistently they saw a doctor or how their diabetes was otherwise managed. The authors' own conclusion is direct about the limits: metabolic improvements may not uniformly translate to musculoskeletal benefit, which is roughly what the diabetes-cohort arthroscopy result suggests^[1].

That caution matters because it is a different kind of evidence than the semaglutide knee osteoarthritis trial published in the New England Journal of Medicine in 2024. That trial, STEP 9, randomized 407 adults with obesity and knee osteoarthritis to semaglutide or placebo and found semaglutide reduced knee pain on the WOMAC scale by 41.7 points versus 27.5 points on placebo at 68 weeks, alongside a 13.7% mean weight loss versus 3.2% on placebo^[2]. STEP 9 is a controlled trial in the knee. The Foot & Ankle Specialist analysis is an observational study in the ankle. The two should not be read as the same evidence for the same joint.

Where ankle osteoarthritis treatment stands, with or without GLP-1 drugs

Ankle osteoarthritis is a different disease profile than the hip and knee versions most people picture when they hear the term. It disproportionately affects younger, active, working-age adults, a distinctly different population than hip and knee osteoarthritis, which typically involve older adults^[3]. In July 2026, the American Academy of Orthopaedic Surgeons published its first clinical practice guideline covering both nonoperative and operative management of ankle osteoarthritis.

The guideline gives a strong recommendation against intra-articular hyaluronic acid used alone, though it notes a possible short-term benefit when combined with a corticosteroid, and a moderate recommendation against routine platelet-rich plasma injections^[3]. Weight reduction, corticosteroid injections, physical therapy and NSAIDs or acetaminophen are covered by weaker consensus statements rather than by graded, evidence-based recommendations, because the guideline panel judged the ankle-specific evidence too thin to grade. For advanced disease, the guideline does not offer a strong evidence-based recommendation for choosing between ankle arthrodesis (fusion) and total ankle arthroplasty (replacement); its authors say future guidelines should take on definitive surgical treatment as more evidence accumulates^[3]. GLP-1 receptor agonists are not addressed in the guideline at all.

What we don't yet know

Whether a GLP-1 receptor agonist changes the course of ankle osteoarthritis specifically, as opposed to knee osteoarthritis, has not been tested in a randomized trial. The Foot & Ankle Specialist study is a first look at treatment patterns in existing health records, and it points in two different directions depending on who is taking the drug and why. No GLP-1 receptor agonist, including semaglutide, is approved by the FDA or EMA for the treatment or prevention of osteoarthritis in any joint, ankle included.

If you are managing ankle osteoarthritis and are also a candidate for a GLP-1 receptor agonist for one of its approved uses, that combination is worth raising with your prescribing clinician and your orthopedic surgeon together, not a reason to start or stop a medication on your own. More on how semaglutide is approved and regulated is on our semaglutide regulation page.